Discussion
Oculis is expanding the clinical development of privosegtor, its experimental nerve-protecting therapy, to include the treatment of acute relapses in people with multiple sclerosis (MS). The move follows the U.S. Food and Drug Administration’s (FDA) clearance of an investigational new drug (IND) application, paving the way for…